摘要
目的探讨女性人乳头瘤病毒(Human papillomavirus,HPV)感染率及其与宫颈细胞病变的关系。方法选择2018-2021年南京市某医院就诊的20-45岁女性,开展宫颈细胞HPV检测和液基薄层细胞检测,分析HPV感染率及其与宫颈细胞病变[包括非典型鳞状细胞病变(ASCUS)、低级别鳞状上皮内病变(LSIL)和高级别鳞状上皮内病变(HSIL)]的相关性。结果本研究中20-45岁女性HPV总感染率为12.08%(2276/18845),其中高危型HPV感染率为9.48%,单一HPV型别感染率为11.63%;常见高危型HPV为HPV52、HPV16和HPV58,感染率分别为2.07%、1.78%和1.36%。12519名女性同时进行了TCT检查,宫颈细胞病变阳性检出率为4.57%,ASCUS、LSIL、HSIL女性HPV感染率分别为46.44%、80.00%和90.48%,其中高危型HPV感染率分别为37.15%、64.44%和85.71%。Pearson相关分析显示HPV危险型分级与宫颈细胞病变程度呈正相关(r=0.34,P=0.000)。结论本研究中20-45岁就诊女性HPV感染率高,宫颈细胞病变程度与HPV危险型分级呈正相关;建议研发适用于20-45岁女性含区域性优势流行株的多价HPV疫苗。
Objective To explore human papillomavirus(HPV)infection and its correlation with cervical lesions.Methods We selected 20-45-year-old females who visited a hospital of Nanjing city during 2018-2021 and screened subjects with the ThinPrep cytology test(TCT)of cervical cells to determine correlation of HPV infection with cervical lesions,including atypical squamous cell lesions(ASCUS),low grade squamous intraepithelial lesions(LSIL),and high grade squamous intraepithelial lesions(HSIL).Results The overall HPV infection rate was 12.08%(2276/18845),and was 9.48%for high-risk HPV types and 11.63%for single infections.The predominant high-risk HPV types were HPV52,HPV16,and HPV58 with infection rates of 2.07%,1.78%,and 1.36%,respectively.Among the 12519 subjects who received TCT,4.57%were positive for cervical cell lesions.HPV infection rates in subjects with ASCUS,LSIL,and HSIL were 46.44%,80.00%,and 90.48%,respectively,with 37.15%,64.44%,and 85.71%having high-risk HPV types.Pearson correlation analysis showed that the grade level of HPV types was positively correlated with the severity of cervical lesions(r=0.34,P=0.000).Conclusions HPV infection was prevalent among 20-45-year-old females.The severity of cervical lesions correlated with HPV risk grade.We suggest developing a multivalent HPV vaccine containing the local predominant strains seen among 20-45-year-old females.
作者
任俊红
凤尔翠
刘巧玲
张翠兰
仇玮
王婕
陈舒
戴家振
Ren Junhong;Feng Ercui;Liu Qiaoling;Zhang Cuilan;Qiu Wei;Wang Jie;Chen Shu;Dai Jiazhen(Nanjing High-tech Zone Hospital,Nanjing 210031,Jiangsu,China;The Affiliated Jiangning Hospital of Nanjing Medical University,Nanjing 211100,Jiangsu,China)
出处
《中国疫苗和免疫》
CSCD
北大核心
2022年第1期68-73,共6页
Chinese Journal of Vaccines and Immunization
基金
长三角免疫规划领军人才研究项目(CSJP005)
2020年四川性社会学和性教育研究中心立项(SXJYZ2106)。
作者简介
第一作者:任俊红,Email:331242258@qq.com。
